Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Scholar Rock Holding Corp SRRK

Healthcare Biotechnology
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled the Company... see more

Recent & Breaking News (NDAQ:SRRK)

Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer

Business Wire September 20, 2022

Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit

Business Wire September 16, 2022

Scholar Rock Reports Second Quarter 2022 Financial Results and Highlights Business Progress

Business Wire August 8, 2022

Scholar Rock Announces the Addition of Srinivas Akkaraju, M.D., Ph.D. to Its Board of Directors

Business Wire July 26, 2022

Scholar Rock to Participate in the 2022 Wedbush PacGrow Healthcare Conference

Business Wire July 19, 2022

Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGFβ1 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference

Business Wire July 15, 2022

Scholar Rock to Present Phase 3 SAPPHIRE Trial Design at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)

Business Wire July 1, 2022

Scholar Rock Announces $205 Million Registered Direct Offering

Business Wire June 17, 2022

Positive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months with Apitegromab for Non-Ambulatory Patients with Types 2 and 3 Spinal Muscular Atrophy (SMA)

Business Wire June 17, 2022

Scholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA Conference

Business Wire June 9, 2022

Scholar Rock to Present at Jefferies Global Healthcare Conference 2022

Business Wire June 2, 2022

Scholar Rock Reports First Quarter 2022 Financial Results and Updates Strategic Priorities

Business Wire May 16, 2022

Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 2022 European Paediatric Neurology Society Congress

Business Wire April 21, 2022

Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the American Academy of Neurology 2022 Annual Meeting

Business Wire March 22, 2022

Scholar Rock to Present Data from TOPAZ Ambulatory Cohort Analysis at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Business Wire March 13, 2022

Scholar Rock Reports Full Year 2021 Financial Results and Highlights Business Progress

Business Wire March 7, 2022

Scholar Rock to Present at Cowen's 42nd Annual Health Care Conference

Business Wire February 25, 2022

Scholar Rock to Present Biomarker Strategy for SRK-181 at the TGFβ for Immuno-Oncology Drug Development Summit

Business Wire January 25, 2022

Scholar Rock Provides Corporate Update and Highlights Priorities for 2022

Business Wire January 10, 2022

Scholar Rock to Present at the 40th Annual J.P. Morgan Healthcare Conference

Business Wire January 4, 2022